Key facts
- This page summarizes Roby Joyce's Form 4 filing for bioAffinity Technologies, Inc. (BIAF).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jul 2024, 18:47.
Roby Joyce - 01 Jul 2024 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)
- Reporting relationship
- Director
- Issuer ticker
- BIAF
- Reported as of
- 01 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2024, 18:47:10 UTC
- Prior SEC filing
- 14 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Maria Zannes, Attorney-in-fact for Roby Joyce
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Roby Joyce filed Form 4 for bioAffinity Technologies, Inc. (BIAF) on 02 Jul 2024.
Change
- Previous filing in this sequence was filed on 14 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIAF
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +33,784
- Change %
- +103%
- Price
- $0.000000
- Shares after
- 66,615
- Date
- 01 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
BIAF
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 583,130
- Date
- 01 Jul 2024
- Ownership
- The Joyce Living Trust
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024.
Footnote F2
Dr. Joyce is the co-Trustee of The Joyce Living Trust (the "Trust"), together with his wife, Joyce M. Joyce, each of whom may act unilaterally with regard to voting and disposition power with respect to the shares owned by the Trust. Dr. Joyce and Mrs. Joyce are the beneficiaries of the Trust.